menu
    • menu
    [{"orgOrder":0,"company":"Cardinal Health","sponsor":"Cardinal Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2015","type":"Inapplicable","leadProduct":"99m-Tc Tilmanocept","moa":"CD206","graph1":"Oncology","graph2":"Phase I","graph3":"Cardinal Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardinal Health \/ Cardinal Health","highestDevelopmentStatusID":"6","companyTruncated":"Cardinal Health \/ Cardinal Health"},{"orgOrder":0,"company":"Cardinal Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2015","type":"Inapplicable","leadProduct":"99m-Tc Tilmanocept","moa":"CD206","graph1":"Oncology","graph2":"Phase II","graph3":"Cardinal Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardinal Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardinal Health \/ Undisclosed"},{"orgOrder":0,"company":"Cardinal Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2015","type":"Inapplicable","leadProduct":"99m-Tc Tilmanocept","moa":"CD206","graph1":"Oncology","graph2":"Phase II","graph3":"Cardinal Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardinal Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardinal Health \/ Undisclosed"},{"orgOrder":0,"company":"Cardinal Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2016","type":"Inapplicable","leadProduct":"99m-Tc Tilmanocept","moa":"CD206","graph1":"Oncology","graph2":"Phase II","graph3":"Cardinal Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardinal Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardinal Health \/ Undisclosed"},{"orgOrder":0,"company":"Cardinal Health","sponsor":"Cardinal Health","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Loxoprofen Sodium","moa":"Cyclooxygenase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Cardinal Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Patch","sponsorNew":"Cardinal Health \/ Cardinal Health","highestDevelopmentStatusID":"8","companyTruncated":"Cardinal Health \/ Cardinal Health"},{"orgOrder":0,"company":"Cardinal Health","sponsor":"Cardinal Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Cardinal Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardinal Health \/ Cardinal Health","highestDevelopmentStatusID":"8","companyTruncated":"Cardinal Health \/ Cardinal Health"},{"orgOrder":0,"company":"Cardinal Health","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Vicineum","moa":"Epithelial cell adhesion molecule","graph1":"Oncology","graph2":"Phase III","graph3":"Cardinal Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardinal Health \/ Sesen Bio","highestDevelopmentStatusID":"10","companyTruncated":"Cardinal Health \/ Sesen Bio"},{"orgOrder":0,"company":"Cardinal Health","sponsor":"Clarity Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2021","type":"Agreement","leadProduct":"67-Cu MeCOSar-Tyr3-octreotate","moa":"SST2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardinal Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cardinal Health \/ Cardinal Health","highestDevelopmentStatusID":"7","companyTruncated":"Cardinal Health \/ Cardinal Health"}]

    Find Clinical Drug Pipeline Developments & Deals by Cardinal Health

    Menu

    Cardinal Health

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cardinal Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cardinal Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cisplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Fox Chase Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer

                            Details : Cisplatin is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Oropharyngeal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            April 05, 2023

                            Lead Product(s) : Cisplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Fox Chase Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cardinal Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cardinal Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 67-Cu MeCOSar-Tyr3-octreotate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Clarity Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Clarity and Cardinal Health Enter into Agreement for Targeted Copper Theranostics

                            Details : Cardinal Health will provide cGMP product manufacturing of ready-to-use TCT for Clarity’s U.S.-based clinical trials from its Center for Theranostics Advancement. TCT are radiopharmaceuticals that pair copper-64 (64Cu) and copper-67 (67Cu) for diagnosi...

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            December 02, 2021

                            Lead Product(s) : 67-Cu MeCOSar-Tyr3-octreotate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Clarity Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cardinal Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cardinal Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vicineum

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Carisma Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sesen Bio Ink Exclusive Agreement With Cardinal Health for Third-Party Logistics and Specialty Pharma Distribu...

                            Details : Cardinal Health will provide comprehensive end-to-end 3PL to Sesen Bio in support of commercialization in the U.S. The Company’s lead program, Vicineum is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, ...

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            October 19, 2020

                            Lead Product(s) : Vicineum

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Carisma Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cardinal Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cardinal Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 99m-Tc Tilmanocept

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identif...

                            Details : 99m-Tc Tilmanocept is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anus Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            August 05, 2016

                            Lead Product(s) : 99m-Tc Tilmanocept

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cardinal Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cardinal Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Loxoprofen Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Recipient : Lead Chemical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pilot Study Comparing the Efficacy and Safety of a New Pain Patch and Placebo in Delayed Onset Muscle Soreness...

                            Details : Loxoprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Muscle Fatigue.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 11, 2015

                            Lead Product(s) : Loxoprofen Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Recipient : Lead Chemical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cardinal Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cardinal Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 99m-Tc Tilmanocept

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : University of California, San Diego

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium

                            Details : 99m-Tc Tilmanocept is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Endometrial Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            October 28, 2015

                            Lead Product(s) : 99m-Tc Tilmanocept

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : University of California, San Diego

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cardinal Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cardinal Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 99m-Tc Tilmanocept

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pa...

                            Details : 99m-Tc Tilmanocept is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Uterine Cervical Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            July 28, 2015

                            Lead Product(s) : 99m-Tc Tilmanocept

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cardinal Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cardinal Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 99m-Tc Tilmanocept

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyos...

                            Details : 99m-Tc Tilmanocept is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhabdomyosarcoma.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            July 28, 2015

                            Lead Product(s) : 99m-Tc Tilmanocept

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth